Our findings emphasize the need to monitor and control CVD risk factors, such as elevated blood glucose, abnormal lipid levels, and changes in kidney function (ie, albuminuria, estimated glomerular filtration rate, and serum creatinine levels), in men with type 2 diabetes and PCa who are receiving GnRH agonists. Here, GNRH1 is linked to posterior cortical atrophy.